| 產(chǎn)品編號(hào) | bsm-33092M-HRP |
| 英文名稱1 | Mouse Anti-XRCC4/HRP Conjugated antibody |
| 中文名稱 | 辣根過(guò)氧化物酶標(biāo)記的DNA修復(fù)基因XRCC4單克隆抗體 |
| 別 名 | X-Ray Repair Cross Complementing 4; X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 4; XRCC4_HUMAN; DNA Repair Protein XRCC4; X-Ray Repair, Complementing Defective, Repair In Chinese Hamster; X-Ray Repair Cross-Complementing Protein 4; SSMED; |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 染色質(zhì)和核信號(hào) |
| 抗體來(lái)源 | Mouse |
| 克隆類型 | Monoclonal |
| 克 隆 號(hào) | 7D11 |
| 交叉反應(yīng) | (predicted: Human, ) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 ELISA=1:100-1000 IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 38kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human XRCC4 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein G |
| 儲(chǔ) 存 液 | Constituents: 0.01M PBS, pH 7.4 with 10 mg/mL BSA and 0.1% Gentamicin, 50% glycerol. Or Lyophilized. Buffer = 0.01M PBS, pH 7.4 with 10 mg/mL BSA and 0.1% Gentamicin. Reconstitute with sterile distilled water. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The protein encoded by this gene functions together with DNA ligase IV and the DNA-dependent protein kinase in the repair of DNA double-strand breaks. This protein plays a role in both non-homologous end joining and the completion of V(D)J recombination. Mutations in this gene can cause short stature, microcephaly, and endocrine dysfunction (SSMED). Alternative splicing generates several transcript variants. [provided by RefSeq, Dec 2015] Function: Involved in DNA non-homologous end joining (NHEJ) required for double-strand break repair and V(D)J recombination. Binds to DNA and to DNA ligase IV (LIG4). The LIG4-XRCC4 complex is responsible for the NHEJ ligation step, and XRCC4 enhances the joining activity of LIG4. Binding of the LIG4-XRCC4 complex to DNA ends is dependent on the assembly of the DNA-dependent protein kinase complex DNA-PK to these DNA ends. Subunit: Homodimer and homotetramer in solution. The homodimer associates with LIG4. The LIG4-XRCC4 complex associates in a DNA-dependent manner with the DNA-PK complex composed of PRKDC, XRCC6/Ku70 and XRCC5/Ku86 to form the core non-homologous end joining (NHEJ) complex. Additional components of the NHEJ complex include NHEJ1/XLF and C9orf142/PAXX. Interacts directly with PRKDC but not with the XRCC6/Ku70 and XRCC5/Ku86 dimer. Interacts with APTX and APLF. Subcellular Location: Nucleus Tissue Specificity: Widely expressed. Post-translational modifications: Phosphorylated by PRKDC. The phosphorylation seems not to be necessary for binding to DNA. Phosphorylation by CK2 promotes interaction with APTX. Monoubiquitinated. Sumoylation at Lys-210 is required for nuclear localization and recombination efficiency. Has no effect on ubiquitination. DISEASE: The disease is caused by mutations affecting the gene represented in this entry. Disease descriptionA disease characterized by short stature and microcephaly apparent at birth, progressive post-natal growth failure, and endocrine dysfunction. In affected adults endocrine features include hypergonadotropic hypogonadism, multinodular goiter, and diabetes mellitus. Variable features observed in some patients are progressive ataxia, and lymphopenia or borderline leukopenia. Similarity: Belongs to the XRCC4 family. Database links: Entrez Gene: 7518 Human Omim: 194363 Human SwissProt: Q13426 Human Unigene: 567359 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
